Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Hadzijusufovic Emir,

** = Publikationen gelistet in SCI/SSCI/Pubmed

2019

Zeitschriftenaufsatz

** Gamperl, S; Stefanzl, G; Peter, B; Smiljkovic, D; Bauer, K; Willmann, M; Valent, P; Hadzijusufovic, E (2019): Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Vet Comp Oncol. 2019; 17(4):553-561
Open Access Logo

** Gleixner, KV; Sadovnik, I; Schneeweiss, M; Eisenwort, G; Byrgazov, K; Stefanzl, G; Berger, D; Herrmann, H; Hadzijusufovic, E; Lion, T; Valent, P (2019): A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. Leuk Res 2019; 78: 36-44.

** Sperr, WR; Kundi, M; Alvarez-Twose, I; van Anrooij, B; Oude Elberink, JNG; Gorska, A; Niedoszytko, M; Gleixner, KV; Hadzijusufovic, E; Zanotti, R; Bonadonna, P; Bonifacio, M; Perkins, C; Illerhaus, A; Elena, C [and 29 others] (2019): International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019; 6(12):e638-e649

** Valent, P; Oude Elberink, JNG; Gorska, A; Lange, M; Zanotti, R; van Anrooij, B; Bonifacio, M; Bonadonna, P; Gleixner, KV; Hadzijusufovic, E; Perkins, C; Hartmann, K; Illerhaus, A; Merante, S; Elena, C [and 33 others] (2019): The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. J Allergy Clin Immunol Pract. 2019; 7(1):81-87

** Willmann, M; Hadzijusufovic, E; Hermine, O; Dacasto, M; Marconato, L; Bauer, K; Peter, B; Gamperl, S; Eisenwort, G; Jensen-Jarolim, E; Müller, M; Arock, M; Vail, DM; Valent, P (2019): Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. Vet Comp Oncol. 2019; 17(1):1-10
Open Access Logo

2018

** Keller, A; Wingelhofer, B; Peter, B; Bauer, K; Berger, D; Gamperl, S; Reifinger, M; Cerny-Reiterer, S; Moriggl, R; Willmann, M; Valent, P; Hadzijusufovic, E (2018): The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma. Vet Comp Oncol. 2018; 16(1):55-68
Open Access Logo

** Peter, B; Bibi, S; Eisenwort, G; Wingelhofer, B; Berger, D; Stefanzl, G; Blatt, K; Herrmann, H; Hadzijusufovic, E; Hoermann, G; Hoffmann, T; Schwaab, J; Jawhar, M; Willmann, M; Sperr, WR [and 7 others] (2018): Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018; 32(4):1016-1022
Open Access Logo

** Schneeweiss, M; Peter, B; Bibi, S; Eisenwort, G; Smiljkovic, D; Blatt, K; Jawhar, M; Berger, D; Stefanzl, G; Herndlhofer, S; Greiner, G; Hoermann, G; Hadzijusufovic, E; Gleixner, KV; Bettelheim, P [and 5 others] (2018): The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica 2018; 103: 799-809
Open Access Logo

** Valent, P; Hadzijusufovic, E; Grunt, T; Karlic, H; Peter, B; Herrmann, H; Eisenwort, G; Hoermann, G; Schulenburg, A; Willmann, M; Hubmann, R; Shehata, M; Selzer, E; Gleixner, KV; Rülicke, T [and 7 others] (2018): Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. Wien Klin Wochenschr 130: 517-529.
Open Access Logo

** Willmann, M; Sadovnik, I; Eisenwort, G; Entner, M; Bernthaler, T; Stefanzl, G; Hadzijusufovic, E; Berger, D; Herrmann, H; Hoermann, G; Valent, P; Rülicke, T (2018): Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. Exp Hematol. 2018; 57:50-59.e6

2017

** Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Hoermann, G; Reifinger, M; Pirker, A; Valent, P; Willmann, M (2017): IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. Vet Comp Oncol. 2017; 15(4):1240-1256
Open Access Logo

** Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Hoermann, G; Grebien, F; Eisenwort, G; Schgoer, W; Herndlhofer, S; Kaun, C; Theurl, M; Sperr, WR; Rix, U; Sadovnik, I; Jilma, B; Schernthaner, GH [and 5 others] (2017): Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017; 31(11):2388-2397
Open Access Logo

** Valent, P; Hadzijusufovic, E; Hoermann, G; Füreder, W; Schernthaner, GH; Sperr, WR; Kirchmair, R; Wolf, D (2017): Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017; 59:47-54

** Valent, P; Herndlhofer, S; Schneeweiß, M; Boidol, B; Ringler, A; Kubicek, S; Gleixner, KV; Hoermann, G; Hadzijusufovic, E; Müllauer, L; Sperr, WR; Superti-Furga, G; Mannhalter, C (2017): TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. Oncotarget. 2017; 8(14):23061-23072
Open Access Logo

** Valent, P; Sotlar, K; Blatt, K; Hartmann, K; Reiter, A; Sadovnik, I; Sperr, WR; Bettelheim, P; Akin, C; Bauer, K; George, TI; Hadzijusufovic, E; Wolf, D; Gotlib, J; Mahon, FX [and 3 others] (2017): Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia. 2017; 31(4):788-797

Kongressbeitrag in einer Zeitschrift

** Schneeweiss, M; Peter, B; Bibi, S; Blatt, K; Jawhar, M; Berger, D; Stefanzl, G; Herndlhofer, S; Sperr, WR; Hadzijusufovic, E; Gleixner, KV; Reiter, A; Arock, M; Valent, P (2017): The Novel Switch Control Inhibitor Dcc-2618 Counteracts Growth and Survival Of Various Neoplastic Cells, Including Mast Cells, Eosinophils, and Monocytes, In Patients With Systemic Mastocytosis. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 276-277. Open Access Logo

Hadzijusufovic E; Hoermann G; Herndlhofer S; Sperr WR; Jilma B; Schernthaner GH; Valent P (2017): Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients During Nilotinib Therapy. 59th Annual ASH Meeting, Atlanta, GA, United States (USA), DEZ 9-12, 2017. Blood (130), S1 1619-1619.

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2017): Effects of ponatinib on endothelial cells may explain the occurrence of vascular adverse events in ponatinib-treated patients with CML. Frühjahrstagung der ÖGHO und der AHOP, Bregenz, Austria, APR 6-8, 2017. memo - Magazine of European Medical Oncology (10) 23-23.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2017): Effects of histamine receptor blockers on growth and IgE-dependent histamine release of canine neoplastic mast cells. 64-64.-Veterinary Cancer Society Congress; OCT 26-28, 2017; Portland, United States (USA).

Hadzijusufovic, E (2017): In vitro Models for Canine Mast Cell Research. -Comparative Oncology Mast Cell Meeti; MAR 24-25, 2017; Vienna, Austria.

Originalbeitrag in Sammelwerk

Hadzijusufovic, E; Willmann, M (2017): Comparing Human Breast Cancer with Canine Mammary Cancer. IN: Jensen-Jarolim, E [Hrsg.]: Comparative medicine : disorders linking humans with their animals. Cham, Switzerland, Springer, pp. 191-207. ISBN: 978-3-319-47005-4.

2016

Zeitschriftenaufsatz

** Peter, B; Winter, GE; Blatt, K; Bennett, KL; Stefanzl, G; Rix, U; Eisenwort, G; Hadzijusufovic, E; Gridling, M; Dutreix, C; Hoermann, G; Schwaab, J; Radia, D; Roesel, J; Manley, PW [and 3 others] (2016): Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016; 30(2):464-472
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Hadzijusufovic, E; Kirchmair, R; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Valent, P (2016): Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego, CA, United States (USA), DEC 03-06, 2016. Blood (128), 22

** Keller, A; Peter, B; Zuber, J; Berger, D; Staber, PB; Bettelheim, P; Valent, P; Hadzijusufovic, E (2016): Targeting of BRD4 as a novel therapeutic concept in JAK2 v617F+MPN. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, Denmark, JUN 09-12, 2016. Haematologica (101), S1 89-89.

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2016): Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. 58th Annual ASH Meeting, San Diego, CA, USA, United States (USA), DEC 3-6, 2016. Blood (128), 22 1883-1883.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Hoermann, G; Reifinger, M; Pirker, A; Valent, P; Willmann M (2016): The Ki-1 antigen (CD30), a novel target in neoplastic canine mast cells, is downregulated by interleukin-4. -LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Blatt, K; Cerny-Reiterer, S; Schwaab, J; Sotlar, K; Eisenwort, G; Stefanzl, G; Hoermann, G; Mayerhofer, M; Schneeweiss, M; Knapp, S; Rülicke, T; Hadzijusufovic, E; Bauer, K; Smiljkovic, D; Willmann, M [and 3 others] (2016): Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastozytosis. 50-50.-Jahrestagung der DGHO, OeGHO, SGMO und SGH; OCT 15, 2016; Leipzig, GERMANY.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2016): Effects of Histamine Receptor Antagonists on Canine Neoplastic Mast Cells. 205-205.-ESVCP - ESVONC Congress; OCT 20-22, 2016; Nantes, FRANCE.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2016): Effects of Histamine Receptor 1 antagonists on growth and survival of canine neoplastic mast cells. 8329-8329.-LBG Meeting for Health Sciences.; NOV 28-29, 2016; Vienna, AUSTRIA.

Keller, A; Peter, B; Zuber, J; Berger, D; Staber, PB; Bettelheim, P; Valent, P; Hadzijusufovic, E (2016): Targeting BRD4 as a potential therapeutic approach in JAK2 V617F+ myeloproliferative neoplasms. 8341-8341.-LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Valent, P; Willmann, M; Bauer, K; Blatt, K; Sotlar, K; Schwaab, J; Hoermann, G; Hadzijusufovic, E; Reiter, A; Horny, H; Rülicke, T (2016): Preclinical evaluation of CD30 as a novel molecular target in systemic mastocytosis. 170-170.-17th Annual Congress of EUSAAT; AUG 24-27, 2016; Linz, AUSTRIA.

2015

Zeitschriftenaufsatz

** Blatt, K; Cerny-Reiterer, S; Schwaab, J; Sotlar, K; Eisenwort, G; Stefanzl, G; Hoermann, G; Mayerhofer, M; Schneeweiss, M; Knapp, S; Rülicke, T; Hadzijusufovic, E; Bauer, K; Smiljkovic, D; Willmann, M [and 3 others] (2015): Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood. 2015; 126(26):2832-2841
Open Access Logo

** Valent, P; Hadzijusufovic, E; Schernthaner, GH; Wolf, D; Rea, D; le Coutre, P (2015): Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015; 125(6):901-906

** Wedeh, G; Cerny-Reiterer, S; Eisenwort, G; Herrmann, H; Blatt, K; Hadzijusufovic, E; Sadovnik, I; Müllauer, L; Schwaab, J; Hoffmann, T; Bradner, JE; Radia, D; Sperr, WR; Hoermann, G; Reiter, A [and 4 others] (2015): Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia. 2015; 29(11):2230-2237
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Keller, A; Peter, B; Zuber, J; Staber, PB; Bettelheim, P; Valent, P; Hadzijusufovic, E (2015): Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+MPN Cells. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, DEC 05-08, 2015. Blood (126), 23

** Keller, A; Peter, B; Zuber, J; Valent, P; Hadzijusufovic, E (2015): Evaluation of BRD4 as potential target in JAK2 V617F+MPN cells. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Basel, Schweiz, Switzerland, OCT 09-13, 2015. Oncol Res Treat (38), S5 226-227.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Sadovnik, I; Jilma, B [and 6 others] (2015): An update of functional data regarding the pro-atherogenic and anti-angiogenic effects of nilotinib in patients with Ph+ CML. Frühjahrstagung der ÖGHO und der AHOP - Oral presentation and Young Investigator Meeting Award, Salzburg, AUSTRIA, Austria, APR 23-25, 2015. memo - Magazine of European Medical Oncology (8), S 1 3-3.

Hadzijusufovic, E; Keller, A; Schur, F; Cerny-Reiterer, S; Hoermann, G; Mayerhofer, M; Boudot, C; Gouilleux, F; Müllauer, L; Moriggl, R; Valent, P (2015): Activated STAT5 as novel stem cell target in JAK2 V617F positive myeloproliferative neoplasms (MPN). 20th Congress of the European Hematology Association, Vienna, AUSTRIA, Austria, JUN 11-14, 2015. Haematologica / The Hematology Journal (100), s1 521-521.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann, M (2015): The Ki-1 antigen (CD30), a novel target in neoplastic canine mast cells, is downregulated by interleukin-4. -Frühjahrstagung der OeGHO & AHOP; APR 23-25, 2015; Salzburg, AUSTRIA.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann; M (2015): The Ki-1 antigen (CD30) is a novel target for brentuximab vedotin in neoplastic canine mast cells. -ESVONC Annual Congress; MAY 28-30, 2015 ; Krakow, POLAND.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann, M. (2015): Interleukin-4 modulates expression of CD30 in neoplastic canine mast cells. -Veterinary Cancer Society; OCT 15-17, 2015; Vienna, VA, USA.

2014

Zeitschriftenaufsatz

** Bibi, S; Arslanhan, MD; Langenfeld, F; Jeanningros, S; Cerny-Reiterer, S; Hadzijusufovic, E; Tchertanov, L; Moriggl, R; Valent, P; Arock, M (2014): Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica. 2014; 99(3):417-429
Open Access Logo

** Cerny-Reiterer, S; Meyer, RA; Herrmann, H; Peter, B; Gleixner, KV; Stefanzl, G; Hadzijusufovic, E; Pickl, WF; Sperr, WR; Melo, JV; Maeda, H; Jäger, U; Valent, P (2014): Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. Oncotarget. 2014; 5(5):1198-1211
Open Access Logo

** Hoermann, G; Gleixner, KV; Dinu, GE; Kundi, M; Greiner, G; Wimazal, F; Hadzijusufovic, E; Mitterbauer, G; Mannhalter, C; Valent, P; Sperr, WR (2014): The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy. 2014; 69(6):810-813
Open Access Logo

** Mirkina, I; Hadzijusufovic, E; Krepler, C; Mikula, M; Mechtcheriakova, D; Strommer, S; Stella, A; Jensen-Jarolim, E; Höller, C; Wacheck, V; Pehamberger, H; Valent, P (2014): Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS One. 2014; 9(1):e84417
Open Access Logo

** Peter, B; Cerny-Reiterer, S; Hadzijusufovic, E; Schuch, K; Stefanzl, G; Eisenwort, G; Gleixner, KV; Hoermann, G; Mayerhofer, M; Kundi, M; Baumgartner, S; Sperr, WR; Pickl, WF; Willmann, M; Valent, P (2014): The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. J Leukoc Biol. 2014; 95(1):95-104

** Saleh, R; Wedeh, G; Herrmann, H; Bibi, S; Cerny-Reiterer, S; Sadovnik, I; Blatt, K; Hadzijusufovic, E; Jeanningros, S; Blanc, C; Legarff-Tavernier, M; Chapiro, E; Nguyen-Khac, F; Subra, F; Bonnemye, P [and 7 others] (2014): A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood. 2014; 124(1):111-120

Kongressbeitrag in einer Zeitschrift

** Blatt, K; Cerny-Reiterer, S; Sotlar, K; Schwaab, J; Hoermann, G; Mayerhofer, M; Hadzijusufovic, E; Willmann, M; Reiter, A; Horny, HP; Valent, P (2014): The KI-1 Antigen (CD30) Is A Novel Marker And Potential Therapeutic Target In Advanced Systemic Mastocytosis. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 514-514.

** Blatt, K; Cerny-Reiterer, S; Sotlar, K; Schwaab, J; Stefanzl, G; Hoermann, G; Mayerhofer, M; Hadzijusufovic, E; Willmann, M; Reiter, A; Horny, HP; Valent, P (2014): Evaluation of the Ki-1 antigen (CD30) as a novel marker and target in advanced mastocytosis. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 219-220.

** Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Sadovnik, I; Hoermann, G; Jilma, B; Sperr, WR [and 6 others] (2014): Pro-Atherogenic And Anti-Angiogenic Effects Of Nilotinib On Endothelial Cells: A Potential Mechanism To Explain Vasculopathies In Cml Patients Treated With Nilotinib. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 510-510.

** Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hormann, G; Jilma, B; Sperr, WR [and 6 others] (2014): Nilotinib exerts proatherogenic and growth-inhibitory effects on endothelial cells: a potential mechanism underlying drug-related vasculopathy in Ph plus CML. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 300-300.

** Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Sadovnik, I; Jilma, B [and 6 others] (2014): Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome plus CML. 56th Annual ASH Meeting, San Francisco, USA, United States (USA), DEC 6-9, 2014. Blood (124), 21 1800.

** Peter, B; Blatt, K; Herrmann, H; Stefanzl, G; Gleixner, KV; Hadzijusufovic, E; Sperr, WR; Schwaab, J; Willmann, M; Reiter, A; Valent, P (2014): The Multikinase Inhibitor R763/AS703569 Blocks Stat5 Activity And Induces Apoptosis In Neoplastic Human Mast Cells. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 126-126.

** Peter, B; Blatt, K; Herrmann, H; Stefanzl, G; Gleixner, KV; Hadzijusufovic, E; Sperr, WR; Schwaab, J; Willmann, M; Reiter, A; Valent, P (2014): Effects of the multikinase inhibitor R763/AS703569 on growth and survival of neoplastic mast cells. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 285-285.

** Wedeh, G; Cerny-Reiterer, S; Hadzijusufovic, E; Eisenwort, G; Herrmann, H; Blatt, K; Muellauer, L; Schwaab, J; Bradner, JE; Sperr, WR; Reiter, A; Horny, HP; Willmann, M; Zuber, J; Arock, M; Valent, P (2014): Bromodomain- containing protein 4 (BRD4): a novel therapeutic target in advanced mast cell neoplasms. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 198-199.

** Wedeh, G; Cerny-Reiterer, S; Hadzijusufovic, E; Herrmann, H; Blatt, K; Eisenwort, G; Hoermann, G; Sperr, WR; Muellauer, L; Vakoc, CR; Bradner, JE; Horny, H; Zuber, J; Arock, M; Valent, P (2014): The Epigenetic Reader Brd4 Serves As A Novel Marker And Target In Aggressive Systemic Mastocytosis And Mast Cell Leukemia. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 514-515.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U [and 5 others] (2014): Nilotinib induces Pro-Atherogenic and Anti-Angiogenic Effects on Human Vascular Endothelial Cells: A Potential Explanation for Drug-induced Vasculopathies in CML Patients. Frühjahrstagung der ÖGHO und der AHOP, Innsbruck, AUSTRIA, Austria, APR 10-12, 2014. Magazine of European Medical Oncology (7), S1 3-3.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Jilma, B; Schernthaner, GH [and 7 others] (2014): Further evaluation of pro-atherogenic and anti-angiogenic effects of nilotinib in mice and in patients with Ph-chromosome+ CML. -56th Annual ASH Meeting; DEC 6-9, 2014; San Francisco, USA.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Jilma, B; Schernthaner, GH [and 7 others] (2014): Nilotinib exerts proatherogenic and growth-inhibitory effects on endothelial cells: a potential mechanism underlying drug-related vasculopathy in Ph+ CML. -Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; OCT 10-14, 2014; Hamburg, GERMANY.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Jilma, B; Schernthaner, GH [and 7 others] (2014): Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib: A Potential Explanation for Atherosclerosis in CML. -LBG Meeting for Health Sciences; DEZ 9-10, 2014; Vienna, AUSTRIA.

Keller, A; Willmann, M; Valent, P; Hadzijusufovic, E (2014): Evaluation of the JAK2-STAT5 pathway as a therapeutic target in canine mastocytomas. -ECVIM-CA congress; SEP 4-6, 2014; Mainz, GERMANY.

2013

Zeitschriftenaufsatz

** Gleixner, KV; Peter, B; Blatt, K; Suppan, V; Reiter, A; Radia, D; Hadzijusufovic, E; Valent, P (2013): Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica. 2013; 98(9):1450-1457
Open Access Logo

** Valent, P; Aberer, E; Beham-Schmid, C; Fellinger, C; Fuchs, W; Gleixner, KV; Greul, R; Hadzijusufovic, E; Hoermann, G; Sperr, WR; Wimazal, F; Wöhrl, S; Zahel, B; Pehamberger, H (2013): Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). Am J Blood Res. 2013; 3(2):174-180 Open Access Logo

Valent, P; Aberer, E; Beham-Schmid, C; Fellinger, C; Fuchs, W; Gleixner, KV; Greul, R; Hadzijusufovic, E; Hoermann, G; Sperr, WR; Wimazal, F; Wohrl, S; Zahel, B; Pehamberger, H (2013): The Austrian Competence Network on Mastocytosis (AUCNM): A partner and part of the European ECNM network. Magazine of European Medical Oncology (6), 2 114-118.

Kongressbeitrag in einer Zeitschrift

** Hadzijusufovic, E; Keller, A; Schur, F; Cerny-Reiterer, S; Sadovnik, I; Pecnard, E; Gouilleux, F; Valent, P (2013): Expression of phosphorylated STAT5 in the putative stem cell population of JAK2 V617F transformed myeloproliferative neoplasms. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, AUSTRIA, Austria, OKT 18-22, 2013. Onkologie (36), S7 288-288.

** Oida, K; Hadzijusufovic, E; Panakova, L; Roth-Walter, F; Singer, J; Fazekas, J; Willmann, M; Szalai, K; Tanaka, A; Matsuda, H; Jensen-Jarolim, E (2013): House dust mite allergens induce IgE-independent activation of canine mast cells NI-1. World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Milan, ITALY, Italy, JUN 22-26, 2013. Allergy (68) 669-669.

** Peter, B; Winter, G; Blatt, K; Rix, U; Benett, K; Stefanzl, G; Hadzijusufovic, E; Dutreix, C; Gross, S; Roesel, J; Manley, P; Superti-Furga, G; Valent, P (2013): Evaluation Of Growth-Inhibitory And Histamine Release-Targeting Effects Of Pkc412 And Its Metabolites On Neoplastic Mast Cells By Chemical Proteomics Profiling And Target Validation. 18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013. Haematologica (98), S1 407-407.

** Peter, B; Winter, G; Blatt, K; Rix, U; Benett, KL; Stefanzl, G; Hadzijusufovic, E; Dutreix, C; Gross, SH; Roesel, J; Manley, P; Superti-Furga, G; Valent, P (2013): Evaluation of the effects of the PKC412-metabolites CGP52421 and CGP62221 on proliferation and viability of neoplastic mast cells and IgE dependent secretion of histamine. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, AUSTRIA, Austria, OCT 18-19, 2013. Onkologie (36) 214-215.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Wojta, J; Wolf, D [and 3 others] (2013): Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects on Vascular Endothelial Cells: A Potential Explanation for Drug-Induced Vasculopathy in CML. -55th Annual ASH Meeting; DEC 7-10, 2013; New Orleans, USA.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Wojta, J; Wolf, D [and 3 others] (2013): Evaluation of potential mechanisms underlying nilotinib-induced vasculopathy in CML: evidence that nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on endothelial cells. -15th ESH - iCMLf International Conference on CML - Biology and Therapy; SEP 26-29, 2013; Estoril, PORTUGAL.

Hadzijusufovic, E; Keller, A; Schur, F; Cerny-Reiterer, S; Sadovnik, I; Pecnard, E; Gouilleux, F; Moriggl, R; Valent, P (2013): Expression of activated STAT5 in the putative stem cell fraction of JAK2 V617F-transformed myeloproliferative neoplasms. -1st LBG Health Sciences Meeting; DEC 2, 2013; Vienna, AUSTRIA.

Hadzijusufovic, E; Schur, F; Cerny-Reiterer, S; Pecnard, E; Gouilleux, F; Valent, P (2013): Expression of activated STAT5 in neoplastic stem cells in JAK2 V617F-transformed myeloproliferative neoplasms. -Second ESH-EHA Scientific Workshop on Leukemic and Cancer Stem Cells: Malignant Stem Cells and their Microenvironment; APR 25-27, 2013; Mandelieu, FRANCE.

2012

Zeitschriftenaufsatz

** Blatt, K; Herrmann, H; Mirkina, I; Hadzijusufovic, E; Peter, B; Strommer, S; Hoermann, G; Mayerhofer, M; Hoetzenecker, K; Klepetko, W; Ghanim, V; Marth, K; Füreder, T; Wacheck, V; Valenta, R; Valent, P (2012): The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One. 2012; 7(1):e29925
Open Access Logo

** Ghanim, V; Herrmann, H; Heller, G; Peter, B; Hadzijusufovic, E; Blatt, K; Schuch, K; Cerny-Reiterer, S; Mirkina, I; Karlic, H; Pickl, WF; Zöchbauer-Müller, S; Valent, P (2012): 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood. 2012; 119(18):4242-4252
Open Access Logo

** Hadzijusufovic, E; Peter, B; Herrmann, H; Rülicke, T; Cerny-Reiterer, S; Schuch, K; Kenner, L; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2012): NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation. Allergy. 2012; 67(7):858-868
Open Access Logo

** Valent, P; Arock, M; Bonadonna, P; Brockow, K; Broesby-Olsen, S; Escribano, L; Gleixner, KV; Grattan, C; Hadzijusufovic, E; Hägglund, H; Hermine, O; Horny, HP; Kluin-Nelemans, HC; Maurer, M; Niedoszytko, M [and 14 others] (2012): European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012; 124(23-24):807-814

2011

** Gleixner, KV; Mayerhofer, M; Cerny-Reiterer, S; Hörmann, G; Rix, U; Bennett, KL; Hadzijusufovic, E; Meyer, RA; Pickl, WF; Gotlib, J; Horny, HP; Reiter, A; Mitterbauer-Hohendanner, G; Superti-Furga, G; Valent, P (2011): KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011; 118(7):1885-1898
Open Access Logo

** Peter, B; Gleixner, KV; Cerny-Reiterer, S; Herrmann, H; Winter, V; Hadzijusufovic, E; Ferenc, V; Schuch, K; Mirkina, I; Horny, HP; Pickl, WF; Müllauer, L; Willmann, M; Valent, P (2011): Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica. 2011; 96(5):672-680
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Ghanim, V; Herrmann, H; Hadzijusufovic, E; Peter, B; Blatt, K; Schuch, K; Cerny-Reiterer, S; Mirkina, I; Heller, G; Zochbauer-Muller, S; Karlic, H; Pickl, WF; Valent, P (2011): 5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States (USA), DEC 10-13, 2011. Blood (118), 21 1478-1478.

** Gleixner, KV; Blatt, K; Peter, B; Hadzijusufovic, E; Valent, P (2011): Ponatinib Exerts Growth-Inhibitory Effects on Neoplstic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States (USA), DEC 10-13, 2011. Blood (118), 21 1492-1492.

** Peter, B; Blatt, K; Stefanzl, G; Hadzijusufovic, E; Dutreix, C; Gross, SH; Roesel, JL; Valent, P (2011): The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States (USA), DEC 10-13, 2011. Blood (118), 21 616-617.

Hadzijusufovic, E; Herndlhofer, S; Aichberger, KJ; Ghanim, V; Suppan, V; Cerny-Reiterer, S; Sperr, WR; Valent, P (2011): Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML. 53rd ASH Annual Meeting and Exposition, San Diego, USA, United States (USA), DEC 10-13, 2011. Blood (118), 21 632-632.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Hadzijusufovic, E; Hörmann, G; Peter, B; Herrmann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Mayerhofer, M; Valent, P (2011): Establishment of Novel Mast Cell Lines. -Annual Meeting of European Competence Network on Mastocytosis; NOV 18-19, 2011; Istanbul, TURKEY.

Hadzijusufovic, E; Mirkina, I; Krepler, C; Mikula, M; Strommer, S; Wacheck, V; Stella, A; Höller, C; Pehamberger, H; Valent, P (2011): Melanoma-Initiating Cells Reside Within the EPOR+ and EPOR- Subfraction of Patient-Derived Clonal Tumor Cells. -Second Workshop Leukemic and Cancer Stem Cells; APR 29 - MAY 1, 2011; Mandelieu, FRANCE.

Dissertation

Hadzijusufovic, Emir (2011): Targeting of the heat shock protein 32 / heme oxygenase 1 in canine neoplastic mast cells is associated with reduced proliferation and induction of apoptosis. Dissertation, Vet. Med. Univ. Wien, pp. 33.

2010

Zeitschriftenaufsatz

** Gleixner, KV; Ferenc, V; Peter, B; Gruze, A; Meyer, RA; Hadzijusufovic, E; Cerny-Reiterer, S; Mayerhofer, M; Pickl, WF; Sillaber, C; Valent, P (2010): Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 2010; 70(4):1513-1523
Open Access Logo

** Hadzijusufovic, E; Peter, B; Gleixner, KV; Schuch, K; Pickl, WF; Thaiwong, T; Yuzbasiyan-Gurkan, V; Mirkina, I; Willmann, M; Valent, P (2010): H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. Exp Hematol. 2010; 38(10):896-907

** Peter, B; Hadzijusufovic, E; Blatt, K; Gleixner, KV; Pickl, WF; Thaiwong, T; Yuzbasiyan-Gurkan, V; Willmann, M; Valent, P (2010): KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Exp Hematol. 2010; 38(9):782-791

Kongressbeitrag in einer Zeitschrift

** Blatt, K; Herrmann, H; Mirkina, I; Hadzijusufovic, E; Peter, B; Marth, K; Valenta, R; Valent, P (2010): The dual PI3 kinase/mTOR inhibitor NVP-BEZ235 acts as a suppressor of growth and function of human mast cells and basophils. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Berlin, Germany, OKT 1-5, 2010. Onkologie (33), Suppl. 6 221-221.

** Peter, B; Gleixner, K; Cerny-Reiterer, S; Herrmann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, W; Pickl, W; Valent, P (2010): Identification Of Polo-Like Kinase-1 (Plk-1) As A Novel Drug Target In Neoplastic Mast Cells In Systemic Mastocytosis. 15th Annual Meeting of the European-Hematology-Association, Barcelona, SPAIN, Spain, JUN 10-13, 2010. Haematol-Hematol J (95), Suppl. 2 0446.

** Peter, B; Gleixner, KV; Cerny-Reiterer, S; Herrmann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Polo-like kinase-1 (Plk-1) is expressed in neoplastic mast cells and is a potential new target in advanced systemic mastocytosis. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Berlin, Germany, OKT 1-5, 2010. Onkologie (33), Suppl. 6 206-206.

** Peter, B; Herrmann, H; Gleixner, KV; Hadzijusufovic, E; Laffer, S; Schuch, K; Pickl, W; Sarno, SM; Willmann, M; Valent, P (2010): The Aurora Kinase Inhibitor R763/AS703569 Exerts Major Growth Inhibitory and Apoptosis Inducing Effects on Neoplastic Mast Cells. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL, DEC 04-07, 2010. Blood (116), 21 1620-1620.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines. 15th Congress of the European Hematology Association, Barcelona, SPAIN, Spain, JUN 10-14, 2010. Haematologica (95), S2 357-357.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines. 357-357.-15th Congress of the European Hematology Association; JUN 10-14, 2010; Barcelona, SPAIN.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT are Associated with Resistance to Sorafenib, Sunitinib, and Masatinib in Neoplastic Mast Cells. 89-89.-6th PhD Symposium, Medical University Vienna; JUN 16-17, 2010; Vienna, AUSTRIA.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): KIT Mutations Predict Resistance to Sorafenib, Sunitinib, and Masatinib in Neoplastic Human and Canine Mast Cells. 17-17.-Frühjahrstagung der ÖGHO und der AHOP; APR 8-10, 2010; Bregenz, AUSTRIA.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): NI-1: A Novel Canine Mast Cell Line with a Unique kit Mutation and Resistance against Masatinib. 228-228.-20th ECVIM-CA Congress; SEP 9-11, 2010; Toulouse, FRANCE.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Identification of Polo-like-kinase-1 (Plk-1) as a novel molecular target in neoplastic mast cells in advanced systemic mastocytosis. -ÖGHO Frühjahrstagung; APR 8-10, 2010; Bregenz, AUSTRIA.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Polo-like kinase 1 (Plk-1) as a novel drug target in canine and human neoplastic mast cells. 228-228.-20th ECVIM-CA Congress; SEP 9-11, 2010; Toulouse, FRANCE.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Identification of Polo-like kinase-1 (Plk-1) as a novel drug target in neoplastic mast cells in systemic mastocytosis. 357-357.-15th Congress of the European Haematology Association; JUN 10-13, 2010; Barcelona, SPAIN.

2009

Zeitschriftenaufsatz

** Gleixner, KV; Mayerhofer, M; Vales, A; Gruze, A; Hörmann, G; Cerny-Reiterer, S; Lackner, E; Hadzijusufovic, E; Herrmann, H; Iyer, AK; Krauth, MT; Pickl, WF; Marian, B; Panzer-Grümayer, R; Sillaber, C [and 3 others] (2009): Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. Curr Cancer Drug Targets. 2009; 9(5):675-689

** Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Thaiwong, T; Pickl, WF; Yuzbasiyan-Gurkan, V; Willmann, M; Valent, P (2009): Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Vet Immunol Immunopathol. 2009; 132(2-4):243-250

** Willmann, M; Müllauer, L; Schwendenwein, I; Wolfesberger, B; Kleiter, M; Pagitz, M; Hadzijusufovic, E; Shibly, S; Reifinger, M; Thalhammer, JG; Valent, P (2009): Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature. In Vivo. 2009; 23(6):911-918 Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Peter, B; Aichberger, K; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The Bh3 Mimetic Gx015-070 (Obatoclax) Induces Apoptosis And Growth Inhibition In Neoplastic Mast Cells. 14th Annual Meeting of the European-Hematology-Association, Berlin, GERMANY, Germany, JUN 04-07, 2009. Haematol-Hematol J (94), Suppl. 2 305.

Hadzijusufovic, E; Gleixner, KV; Peter, B; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The H1 Receptor Antagonists Terfendine and Loratadine inhibit Growth and induce Apoptosis in Neoplastic Mast Cells. Annual Meeting of the Austrian Society of Haematology and Oncology, Salzburg, AUSTRIA, Austria, APR 16-18, 2009. memo - Magazine of European Medical Oncology (2), S 2 6-6.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Gleixner, KV; Gruze, A; Kneidinger, M; Thaiwong, T; Pickl, WF; Yuzbasiyan-Gurkan, V; Willmann, M; Valent, P (2009): Antiproliferative Effects of Four Tyrosine Kinase Inhibitors on Neoplastic Feline Mast Cells Exhibiting a kit Exon-8 ITD Mutation. 267-267.-19th ECVIM-CA Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Hadzijusufovic, E; Peter, B; Willmann, M; Valent, P (2009): Effects of Histamine Recepter Antagonists on Growth and Survival of Neoplastic Mast Cells. -Annual Meeting of European Competence Network on Mastocytosis; NOV 13-14, 2009; Gdansk, POLAND.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Gruze, A; Pickl, WF; Willmann, M; Valent, P (2009): The BH3 Mimetic GX015-070 (Obatoclax) induces Apoptosis and Growth Inhibition in Neoplastic Mast Cells. -14th Congress of the European Hematology Association; JUN 4-7, 2010; Berlin, GERMANY.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The BH3 Mimetic Obatoclax induces Apoptosis and Growth Inhibition in Human and Canine Neoplastic Mast Cells. 233-233.-19th ECVIM-CA Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The pan Bcl-2 inhibitor Obatoclax induces apoptosis and growth arrest in neoplastic mast cells in systemic mastocytosis. -7th Congress of the European Competence Network on Mastocytosis (ECNM); NOV 12-13, 2009; Gdansk, POLAND.

Peter, B; Hadzijusufovic, E; Schuch, K; Blatt, K; Gleixner, KV; Pickl, WF; Willmann, M; Valent, P (2009): Evaluation of antineoplastic effects of INNO-406 on human and canine neoplastic mast cells. -Frühjahrstagung der ÖGHO und der AHOP; APR 12-14, 2009; Salzburg, AUSTRIA.

2008

Zeitschriftenaufsatz

** Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Ferenc, V; Peter, B; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Mayerhofer, M; Samorapoompichit, P; Greish, K; Iyer, AK; Pickl, WF; Maeda, H [and 2 others] (2008): Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. ESVONC spring meeting, Cambridge, UK, United Kingdom, März 23-26, 2007. Exp Hematol. 2008; 36(11):1461-1470

Kongressbeitrag in einer Zeitschrift

** Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2008): Identifi cation of heat shock protein (Hsp32) as a novel therapeutic target in neoplastic mast cells. ESVONC autumn meeting, Budapest, Hungary, Hungary, 13–15 September, 2007. Vet Comp Oncol (6), 1 84-85.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent, P (2008): Antiproliferative Effects of KIT Tyrosine Kinase Inhibitors in Feline Neoplastic Mast Cells. Frühjahrstagung 2008 der Österreichischen Gesellschaft für Hämatologie und Onkologie und der Arbeitsgemeinschaft hämato-onkologischer Pflegepersonen in Österreich (AHOP), Innsbruck, Austria, Austria, APR 10-12, 2008. Magazine of European Medical Oncology (1), Suppl. 1 10-10.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Hadzijusufovic, E; Gleixner, KV; Gruze, A; Kneidinger, M; Baumgartner, C; Pickl, WF; Willmann, M; Valent, P (2008): The H1-Receptor Antagonists Loratadine and Terfenadine inhibit Proliferation and Survival of Neoplastic Mast Cells. 53-53.-ESVONC and VCS First Joint Meeting; FEB 28 - MAR 1, 2008; Copenhagen, DENMARK.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent (2008): Identification of the Tyrosine Kinase Receptor Kit as a Molecular Target in Neoplastic Ferline Mast Cells. 98-98.-28th Annual VCS Conference; OCT 18-21, 2008; Seattle, USA.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent, P (2008): Evaluation of growth-inhibitory effects of kit tyrosine kinase inhibitors on feline neoplastic mast cells. 215-215.-18th ECVIM-CA Congress; SEP 4-6, 2008; Ghent, BELGIUM.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Konto, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2008): Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Canine Mastocytoma Cells. 28-29.-4th PhD Symposium, Medical University of Vienna; MAY 28-29, 2008; Vienna, AUSTRIA.

2007

Zeitschriftenaufsatz

** Gleixner, KV; Rebuzzi, L; Mayerhofer, M; Gruze, A; Hadzijusufovic, E; Sonneck, K; Vales, A; Kneidinger, M; Samorapoompichit, P; Thaiwong, T; Pickl, WF; Yuzbasiyan-Gurkan, V; Sillaber, C; Willmann, M; Valent, P (2007): Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol. 2007; 35(10):1510-1521

Kongressbeitrag in einer Zeitschrift

** Hadzijusufovic, EH; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samoorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Hiroshi, M; Willman, M; Valent, P (2007): Identification of heme oxygenase-1 (HO-1=Hsp32) as a novel therapeutic target in canine mastocytoma cells. 12th Congress of the European Hematology Association, Vienna, Austria, Austria, June 7 – 10, 2007 . Haematol-Hematol J (92) 489-490.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2007): Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Canine Mastocytoma Cells. ÖGHO und AHOP Frühjahrstagung, Vienna, AUSTRIA, Austria, Apr 12-14, 2007 . Wiener medizinische Wochenschrift / Supplement (157), 121 16.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R;Gruze, A; Kneidinger, M;Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2007): Identification of Heat Shock Protein (Hsp32) as a Novel Therapeutic Target in Neoplastic Mast Cells. 194--17th ECVIM-CA Congress; Sep 13-15, 2007; Budapest, HUNGARY.

© Veterinärmedizinische Universität Wien Hilfe und Downloads